Biocryst Pharmaceuticals, Inc.
Corporate Office
Why pick this one
BioCryst Pharmaceuticals, Inc. develops rare-disease therapeutics, including approved ORLADEYO for HAE and RAPIVAB for influenza.
Best for
- Hereditary angioedema therapeutics
- Rare disease drug development
- Netherton syndrome research
- Influenza antiviral treatment
- Patient advocacy related to rare diseases
Look elsewhere if
- Local pharmacy services
- Direct medical diagnosis or treatment
- General corporate office rental or workspace needs
Specialties
- hereditary angioedema therapeutics
- Netherton syndrome drug development
- influenza antiviral treatment
- oral small-molecule therapeutics
- injectable protein therapeutics
What makes them different
- Founded in 1986 and operating as an independent global biotechnology company
- Develops oral small-molecule and injectable protein therapeutics
- ORLADEYO is approved for prophylaxis to prevent hereditary angioedema attacks
- RAPIVAB is approved for treatment of acute uncomplicated influenza
- Pipeline includes navenibart for hereditary angioedema and BCX17725 for Netherton syndrome
Distilled from this business's own website.
Contact & Location
- Address
- 4505 Emperor Blvd Ste 200, Durham, NC 27703-8457
- Phone
- 19198591302
- Website
- https://www.biocryst.com
Services
- drug discovery
- drug development
- therapeutic commercialization
- rare disease research
- patient advocacy